ANG Lifesciences India Ltd
Incorporated in 2006, ANG Lifesciences India Ltd manufactures and markets finished pharmaceutical formulations in a dosage form of sterile dry powder injection vials[1]
- Market Cap ₹ 34.3 Cr.
- Current Price ₹ 26.3
- High / Low ₹ 42.5 / 21.0
- Stock P/E
- Book Value ₹ 45.2
- Dividend Yield 0.00 %
- ROCE -4.18 %
- ROE -17.0 %
- Face Value ₹ 10.0
Pros
- Stock is trading at 0.58 times its book value
Cons
- Company has low interest coverage ratio.
- Company has a low return on equity of -8.77% over last 3 years.
- Promoters have pledged 44.9% of their holding.
- Company has high debtors of 262 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|
| 154 | 354 | 220 | 145 | 93 | 92 | |
| 140 | 286 | 205 | 135 | 94 | 94 | |
| Operating Profit | 14 | 68 | 15 | 10 | -1 | -2 |
| OPM % | 9% | 19% | 7% | 7% | -2% | -2% |
| 1 | 1 | 10 | -1 | 2 | 1 | |
| Interest | 4 | 9 | 12 | 11 | 9 | 8 |
| Depreciation | 1 | 6 | 9 | 8 | 7 | 6 |
| Profit before tax | 10 | 54 | 3 | -11 | -16 | -16 |
| Tax % | 31% | 25% | 110% | -5% | -21% | |
| 7 | 40 | -0 | -10 | -12 | -12 | |
| EPS in Rs | 5.26 | 31.02 | -0.20 | -7.77 | -9.50 | -9.35 |
| Dividend Payout % | 0% | 3% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -36% |
| TTM: | -14% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 6% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | -3% |
| 3 Years: | -36% |
| 1 Year: | -38% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -9% |
| Last Year: | -17% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|
| Equity Capital | 10 | 13 | 13 | 13 | 13 |
| Reserves | 73 | 73 | 63 | 51 | 46 |
| 77 | 71 | 73 | 83 | 90 | |
| 130 | 119 | 92 | 82 | 94 | |
| Total Liabilities | 290 | 276 | 241 | 230 | 243 |
| 93 | 88 | 58 | 57 | 54 | |
| CWIP | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 |
| 198 | 188 | 183 | 172 | 189 | |
| Total Assets | 290 | 276 | 241 | 230 | 243 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| 25 | 26 | -9 | -0 | ||
| -44 | -9 | 20 | -2 | ||
| 20 | -17 | -10 | 2 | ||
| Net Cash Flow | 0 | -0 | -0 | -0 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| Debtor Days | 105 | 138 | 184 | 262 | |
| Inventory Days | 59 | 118 | 183 | 331 | |
| Days Payable | 113 | 165 | 254 | 405 | |
| Cash Conversion Cycle | 51 | 91 | 113 | 189 | |
| Working Capital Days | 20 | 24 | 58 | 55 | |
| ROCE % | 9% | 1% | -4% |
Documents
Announcements
-
Board Meeting Intimation for Consideration And Approval Of The Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter Ended And Nine Months Ended On 31St December, 2025.
1d - Board meeting 14-Feb-2026 to approve Q3/9M FY2026 unaudited results (ended 31-Dec-2025); trading window closed.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
22 Jan - RTA Bigshare certificate under SEBI Reg 74(5) confirming demat compliance for quarter ended 31 Dec 2025.
- Closure of Trading Window 22 Dec 2025
- Unaudited Financial Results For The Quarter And Half Year Ended 30-09-2025 14 Nov 2025
-
Board Meeting Outcome for Board Meeting Outcome For To Consider And Approve The Financial Results For The Quarter And Half Year Ended 30-09-2025
14 Nov 2025 - Unaudited Q2/H1 results to 30 Sep 2025; consolidated Q2 loss Rs321.40 lakh; board approved 14 Nov 2025.
Business Overview:[1][2]
Company manufactures and sells products like injections, tablets, capsules, syrups, ointments of different varieties. It deals in 4 market segments: institutional segment, third party manufacturing, direct marketing and export market. Apart from this, company is also providing printing & packing solutions especially in mono cartons, paper printing, corrugation, aluminiumfoils (blister foils)